# Santen Pharmaceutical Co., Ltd. clinical trials: 30 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 30 trials with Santen Pharmaceutical Co., Ltd. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Santen Pharmaceutical Co., Ltd.: 30 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/santen-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 4, 2025 | NCT06911216 | A Pharmacokinetics (PK) Study in Healthy Adults | Santen Pharmaceutical Co., Ltd. | Early phase 1 | Completed | Blepharoptosis | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06911216) |
| November 12, 2024 | NCT06683651 | A Study in Chinese Patients With Acquired Blepharoptosis | Santen Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Blepharoptosis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06683651) |
| October 31, 2024 | NCT06666855 | A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China | Santen Pharmaceutical Co., Ltd. | Phase 3 | Active not recruiting | Open Angle Glaucoma, Ocular Hypertension | 345 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06666855) |
| June 15, 2023 | NCT05905653 | Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers | Santen Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Adult Males Volunteers | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05905653) |
| August 17, 2022 | NCT05503901 | A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Open Angle Glaucoma, Ocular Hypertension | 131 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05503901) |
| August 10, 2022 | NCT05495061 | A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Primary Open Angle Glaucoma, Ocular Hypertension | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05495061) |
| January 30, 2019 | NCT03822559 | A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Open-angle Glaucoma, Ocular Hypertension | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03822559) |
| November 6, 2017 | NCT03329638 | A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE) | Santen Pharmaceutical Co., Ltd. | Phase 2 | Completed | Myopia | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03329638) |
| July 13, 2017 | NCT03216096 | Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease | Santen Pharmaceutical Co., Ltd. | Phase 1 | Completed | Dry Eye Disease | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03216096) |
| December 5, 2016 | NCT02981446 | A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects... | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Open Angle Glaucoma or Ocular Hypertension | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02981446) |
| September 2, 2016 | NCT02888210 | A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Cataract | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02888210) |
| July 4, 2016 | NCT02822742 | A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Primary Open Angle Glaucoma or Ocular Hypertension | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02822742) |
| July 4, 2016 | NCT02822729 | A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic... | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Open Angle Glaucoma or Ocular Hypertension | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02822729) |
| January 8, 2016 | NCT02650063 | A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study - | Santen Pharmaceutical Co., Ltd. | Phase 1 | Completed | Healthy Male Adults | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02650063) |
| December 8, 2015 | NCT02623738 | A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension... | Santen Pharmaceutical Co., Ltd. | Phase 2/3 | Completed | Primary Open Angle Glaucoma, Ocular Hypertension | 253 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02623738) |
| October 12, 2015 | NCT02573610 | Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Cataract Surgery | 576 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02573610) |
| March 27, 2014 | NCT02097537 | Study of Methacholine Chloride Inhalation Challenge in Children With Bronchial Asthma | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Asthma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02097537) |
| January 19, 2012 | NCT01512901 | Efficacy and Safety of Betamethasone Microsphere in Patients With Macular Edema Following Branch Retinal Vein Occlusion (HIKARI) | Santen Pharmaceutical Co., Ltd. | Phase 2/3 | Completed | Macular Edema Following Branch Retinal Vein Occlusion | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01512901) |
| August 8, 2011 | NCT01411254 | Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA) | Santen Pharmaceutical Co., Ltd. | Phase 2/3 | Completed | Diabetic Macular Edema | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01411254) |
| June 1, 2011 | NCT01363713 | A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Allergic Conjunctivitis | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01363713) |
| June 1, 2011 | NCT01363700 | Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Allergic Conjunctivitis | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01363700) |
| April 27, 2011 | NCT01343082 | DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Open Angle Glaucoma or Ocular Hypertension | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01343082) |
| April 26, 2011 | NCT01342094 | DE-111 Against Timolol Ophthalmic Solution 0.5% | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Open Angle Glaucoma, Ocular Hypertension | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01342094) |
| April 26, 2011 | NCT01342081 | DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol... | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Open Angle Glaucoma, Ocular Hypertension | 489 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01342081) |
| November 15, 2010 | NCT01240382 | Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye | Santen Pharmaceutical Co., Ltd. | Phase 3 | Completed | Dry Eye | 332 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01240382) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 3 |
| Phase 2 | 5 |
| Phase 2/3 | 3 |
| Phase 3 | 17 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 28 |
| Recruiting | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Glaucoma, Open-Angle | 13 |
| Ocular Hypertension | 13 |
| Dry Eye Syndromes | 4 |
| Conjunctivitis, Allergic | 2 |
| Blepharoptosis | 2 |
| Asthma | 1 |
| Glaucoma | 1 |
| Cataract | 1 |
| Myopia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Wholesale florists in the United States](https://specstream.ai/data/businesses/wholesale-florists/united-states)
- [Entertainment law firms in the United States](https://specstream.ai/data/businesses/entertainment-law-firms/united-states)
- [Pediatric surgery practices in the United States](https://specstream.ai/data/businesses/pediatric-surgery-practices/united-states)
- [AV equipment rental companies in the United States](https://specstream.ai/data/businesses/av-equipment-rental-companies/united-states)
- [Genetics practices in the United States](https://specstream.ai/data/businesses/genetics-practices/united-states)
